GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.

The group’s point-of-care Car-T push looks to have stalled.

The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.

After earlier masked probody setbacks, CytomX surprises with CX-2051.

Minghui’s MHB088C will soon start phase 3 in China.

Imfinzi hits on disease-free survival, but BCG won't be displaced.